← Leaderboards
Venkatesh Sampath
Children'S Mercy Hosp (Kansas City, Mo)
$7,069,319
Attributed
$10,323,762
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,323,762 · 7
By mechanism
R01$9,727,722 · 5
R21$446,100 · 1
R03$149,940 · 1
Top collaborators
- Donald B Defranco5 shared
- A Paula Monaghan-Nichols5 shared
- Shahid Umar5 shared
Most similar at Children'S Mercy Hosp (Kansas City, Mo)
Same institution · by research overlap
- Tamorah R Lewis$695,170
Others in their field
Top investigators on “Premature Infant”
- Elizabeth A Thom · George Washington University$118,776,833
- Rebecca Gersnoviez Clifton · George Washington University$73,348,985
- Abhik Das · Research Triangle Institute$34,934,786
- Leonardo Trasande · New York University School Of Medicine$26,043,041
- Jack L. Feldman · University Of California Los Angeles$25,357,911
- Alan Thevenet N. Tita · University Of Alabama At Birmingham$24,173,322
Research focus
Premature InfantMediatingPreventNeonatalInflammationMolecularLungBronchopulmonary DysplasiaIn VitroInfantSignal TransductionResponseProgramsReceptorLigandsNovel TherapeuticsInsightPathogenesisAcuteGrowthGenesFutureLung DiseasesInjury
Grant awards (24)
SIGIRR in the Neonatal Intestine$630,847
R01 · FY2025 · DK · contact PI
DLL4 in the Developing Lung and Bronchopulmonary Dysplasia (BPD)$566,447
R01 · FY2025 · HL · contact PI
A Safer Glucocorticoid to Treat Neonatal Lung Injury with Limited Adverse Neurologic Effects$550,615
R01 · FY2025 · HD
Inhaled ciclesonide - a phase I study in preterm infants$195,800
R21 · FY2025 · HD · contact PI
A Safer Glucocorticoid to Treat Neonatal Lung Injury with Limited Adverse Neurologic Effects$579,211
R01 · FY2024 · HD
DLL4 in the Developing Lung and Bronchopulmonary Dysplasia (BPD)$561,247
R01 · FY2024 · HL · contact PI
Inhaled ciclesonide - a phase I study in preterm infants$250,300
R21 · FY2024 · HD · contact PI
A Safer Glucocorticoid to Treat Neonatal Lung Injury with Limited Adverse Neurologic Effects$600,982
R01 · FY2023 · HD
DLL4 in the Developing Lung and Bronchopulmonary Dysplasia (BPD)$592,536
R01 · FY2023 · HL · contact PI
A Safer Glucocorticoid to Treat Neonatal Lung Injury with Limited Adverse Neurologic Effects$593,864
R01 · FY2022 · HD
Single Immunoglobulin Interleukin-1 Related Receptor and necrotizing enterocolitis in premature infants$501,668
R01 · FY2022 · DK · contact PI
A Safer Glucocorticoid to Treat Neonatal Lung Injury with Limited Adverse Neurologic Effects$606,797
R01 · FY2021 · HD
Single Immunoglobulin Interleukin-1 Related Receptor and necrotizing enterocolitis in premature infants$514,112
R01 · FY2021 · DK · contact PI
Single Immunoglobulin Interleukin-1 Related Receptor and necrotizing enterocolitis in premature infants$515,604
R01 · FY2020 · DK · contact PI
Inflammatory Angiogenesis in the Lung$371,850
R01 · FY2020 · HL · contact PI
Single Immunoglobulin Interleukin-1 Related Receptor and necrotizing enterocolitis in premature infants$533,316
R01 · FY2019 · DK · contact PI
Inflammatory Angiogenesis in the Lung$365,172
R01 · FY2019 · HL · contact PI
Single Immunoglobulin Interleukin-1 Related Receptor and necrotizing enterocolitis in premature infants$535,560
R01 · FY2018 · DK · contact PI
Inflammatory Angiogenesis in the Lung$369,233
R01 · FY2018 · HL · contact PI
Inflammatory Angiogenesis in the Lung$367,631
R01 · FY2017 · HL · contact PI
Inflammatory Angiogenesis in the Lung$370,663
R01 · FY2015 · HL · contact PI
Inflammatory Angiogenesis in the Lung$367
R01 · FY2015 · HL · contact PI
Lipopolysaccharide-mediated oxidative stress and pulmonary vascular injury in Bro$73,440
R03 · FY2011 · HD · contact PI
Lipopolysaccharide-mediated oxidative stress and pulmonary vascular injury in Bro$76,500
R03 · FY2010 · HD · contact PI